Renal Failure, Chronic Clinical Trial
Official title:
The Effect of Intravenous n-3 Polyunsaturated Fatty Acids on Risk Markers for Sudden Cardiac Death in Hemodialysis Patients
The main purpose of this study is to investigate whether intravenous infusion of a lipid emulsion with a high content of n-3 polyunsaturated fatty acids can improve heart rate variability and ventricular repolarization and reduce ventricular arrhythmias in hemodialysis patients.
Cardiovascular disease is the most common cause of death in haemodialysis (HD)patients, and
half of these deaths are due to sudden cardiac death caused by ventricular arrhythmias. HD
patients have an attenuated heart rate variability (HRV) and a high frequency of ventricular
arrhythmias, both of which are predictors of sudden cardiac death(SCD). n-3 polyunsaturated
fatty acids (PUFA) improves HRV and reduces the risk of SCD. n-3 PUFAs are obtained from
fatty fish and fish oil and are incorporated into cell membranes after long-term ingestion.
However, it is not known if this incorporation is essential or merely serves as storage for
n-3 free PUFAs to be release during for instance myocardial ischaemia.
The study hypothesis is that intravenous infusion of a lipid emulsion with a high content of
n-3 PUFAs will improve HRV and ventricular repolarization and reduce ventricular arrhythmias
via an acute increase in free non-esterified n-3 PUFAs in plasma.
In a randomized, placebo-controlled design a n-3 PUFA rich emulsion (or placebo) will be
administered during hemodialysis treatment. The two study groups will be compared with
respect to heart rate variability, ventricular repolarization parameters, ventricular
ectopic beats and arrhythmias and the content of n-3 PUFA in plasma and cell membranes will
be compared.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00176059 -
Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients
|
Phase 0 | |
Completed |
NCT00438503 -
Glucose in Dialysis Water in Diabetics With Chronic Renal Failure
|
Phase 4 | |
Completed |
NCT00439023 -
Glucose in Dialysis Water in Non-diabetics
|
Phase 4 | |
Completed |
NCT03904836 -
Tobramycin Administered at the Beginning of Dialysis
|
Phase 1 | |
Not yet recruiting |
NCT02259296 -
Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure
|
N/A | |
Completed |
NCT00150891 -
Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection
|
N/A | |
Completed |
NCT01875523 -
PK of Serelaxin in Severe Renal Impairment and ESRD
|
Phase 1 | |
Completed |
NCT00438295 -
Temperature Control During Dialysis Treatment
|
Phase 4 | |
Terminated |
NCT00664066 -
DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
|
||
Withdrawn |
NCT00262353 -
Elimination of Protein-bound Uremic Retention Solutes by Prometheus Artificial Hepatic System Versus Conventional Dialysis
|
N/A |